• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by iRadimed Corporation

    11/6/24 12:14:22 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care
    Get the next $IRMD alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001222060
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    IRADIMED CORP
    SEC File Number
    001-36534
    Address of Issuer
    1025 WILLA SPRINGS DR.
    WINTER SPRINGS
    FLORIDA
    32708
    Phone
    4076778022
    Name of Person for Whose Account the Securities are To Be Sold
    VUOTO ANTHONY
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Raymond James & Associates
    880 Carillon Parkway
    St. Petersburg � FL � 33716
    2690150616.061267000011/06/2024
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common12/06/2019RSU VestIssuerCheckbox not checked269011/06/2024Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    11/06/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Maressia Rooks-Bailey, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Anthony Vuoto

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $IRMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IRMD

    DatePrice TargetRatingAnalyst
    4/12/2023$50.00Buy
    Lake Street
    More analyst ratings

    $IRMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System

      WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ:IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed's unique position as the world's only supplier of non-magnetic MRI infusion pump devices, established with our first-generation device in 2005. The MRidium® 3870 is poised to strengthen Iradimed's leadership for MRI-compatible infusion, addressing growing demands for safe and reliable fluid delivery in diagnostic imagi

      5/29/25 8:30:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

      Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the second quarter of 2025, payable on May 30, 2025. WINTER SPRINGS, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its

      5/5/25 7:00:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

      WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ:IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025".  The corrected release follows: IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Monday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conferen

      4/28/25 9:53:08 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Glenn John converted options into 5,796 shares and covered exercise/tax liability with 1,412 shares, increasing direct ownership by 50% to 13,151 units (SEC Form 4)

      4 - IRADIMED CORP (0001325618) (Issuer)

      6/23/25 8:00:21 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 4 filed by CHIEF FINANCIAL OFFICER Glenn John

      4/A - IRADIMED CORP (0001325618) (Issuer)

      4/7/25 4:10:04 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • Amendment: Director Hawkins James B converted options into 1,196 shares, increasing direct ownership by 4% to 33,545 units (SEC Form 4)

      4/A - IRADIMED CORP (0001325618) (Issuer)

      4/4/25 4:45:06 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on iRadimed with a new price target

      Lake Street initiated coverage of iRadimed with a rating of Buy and set a new price target of $50.00

      4/12/23 9:17:10 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    SEC Filings

    See more
    • iRadimed Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - IRADIMED CORP (0001325618) (Filer)

      6/23/25 9:49:42 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • iRadimed Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - IRADIMED CORP (0001325618) (Filer)

      5/29/25 4:15:13 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by iRadimed Corporation

      10-Q - IRADIMED CORP (0001325618) (Filer)

      5/5/25 4:30:33 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Leadership Updates

    Live Leadership Updates

    See more
    • IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors

      WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent. "We are pleased to welcome Hilda Scharen-Guivel to the Iradimed Board," said Roger Susi, President and Chief Executive Officer of the Company. "Hilda's deep experience in regulatory oversight in the medical device industry will be invaluable to Iradimed as we develop new products and grow our business to better serve patients." Ms. Scharen-Guivel,

      10/6/22 4:05:00 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • Perimeter Medical Imaging AI Appoints Experienced MedTech Executive, Chris Scott, as Chief Financial Officer

      Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the appointment of Chris Scott as Chief Financial Officer, effective immediately. Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are pleased to welcome Chris to the Perimeter leadership team. Chris is a collaborative leader who brings a wealth of public company experience directly relevant to Perimeter as we continue to execute on our commercial, clinical, and corporate development goals. Previously

      6/1/22 9:35:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Financials

    Live finance-specific insights

    See more
    • IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

      Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the second quarter of 2025, payable on May 30, 2025. WINTER SPRINGS, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its

      5/5/25 7:00:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

      WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ:IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025".  The corrected release follows: IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Monday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conferen

      4/28/25 9:53:08 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

      WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI1cddc009ba2b427a81ea445f5669adffOnce registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-

      4/28/25 8:30:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by iRadimed Corporation

      SC 13G/A - IRADIMED CORP (0001325618) (Subject)

      11/14/24 3:35:27 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

      SC 13G/A - IRADIMED CORP (0001325618) (Subject)

      2/13/24 4:25:25 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

      SC 13G/A - IRADIMED CORP (0001325618) (Subject)

      2/12/24 12:03:30 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care